CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 26/Jul 00:00
US FDA approves BioMarin's Brineura for children under 3 years with CLN2 disease
BioMarin Pharmaceutical Inc. announced that the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for Brineura (cerliponase alfa) to
Articles similaires
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
haei.org - 03/Sep 17:29
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
drugs.com - 12/Sep 08:09
South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S....
FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
drugs.com - 12/Sep 08:09
South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S....
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
drugs.com - 13/Sep 07:09
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
drugs.com - 13/Sep 07:09
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA extends review period for Medexus’ treosulfan to 2025
themarketherald.ca - 17:41
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
FDA extends review period for Medexus’ treosulfan to 2025
themarketherald.ca - 17:41
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
US: Biden-Harris administration marks major milestones for offshore wind, approves tenth project
energy pedia.com - 05/Sep 17:11
The Biden-Harris administration has announced the approval of the Maryland Offshore Wind Project – the nation’s tenth commercial-scale offshore...
Indoco Remedies receives US FDA final approval to market generic Lucemyra tablets
pharmabiz.com - 11/Sep 12:11
Indoco Remedies Limited (Indoco) announced the receipt of final approval from the US FDA for Abbreviated New Drug Application (ANDA) for lofexidine...
Les derniers communiqués
-
Aucun élément